Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway

Publisher： Bentham Science Publishers

E-ISSN： 2212-3970|4|1|28-35

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.4, Iss.1, 2009-01, pp. : 28-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer

By                    

International Journal of Oncology, Vol. 44, Iss. 2, 2014-01 ,pp. : 481-490

Spandidos Publications

Access to resources Recommend Favorite

Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs)

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 2, 2010-06 ,pp. : 109-141

Bentham Science Publishers

Access to resources Recommend Favorite

Ocular albinism type 1induced melanoma cell migration is mediated through the RAS/RAF/MEK/ERK signaling pathway

By            

Molecular Medicine Reports, Vol. 10, Iss. 1, 2014-01 ,pp. : 491-495

Spandidos Publications

Access to resources Recommend Favorite

Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 6, Iss. 2, 2011-05 ,pp. : 210-236

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Developments of Steroid Sulfatase Inhibitors as Anti-Cancer Agents

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 8, Iss. 7, 2008-10 ,pp. : 732-738

Bentham Science Publishers

Access to resources Recommend Favorite